EC-18 Yields Positive Results for Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer
October 21st 2021A phase 2 trial examining the use of small molecule immunomodulator EC-18 in patients with head and neck cancer experiencing chemoradiation-induced oral mucositis met its primary and secondary end points.
Luciano Costa, MD, PhD, Shares Key Takeaways From the MASTER Trial in Multiple Myeloma
October 19th 2021CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to discuss the benefit of treatment with daratumumab, carfilzomib, lenalidomide, and dexamethasone and the population of patients with newly diagnosed myeloma who will best benefit from treatment.
Between the Lines Podcast: PET/CT-Guided Postprostatectomy Salvage Radiotherapy for Prostate Cancer
October 19th 2021Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, discussed the phase 2/3 EMPIRE-1 trial focusing on 18F-fluciclovine PET/CT imaging versus conventional imaging to guide postprostatectomy salvage radiotherapy for patients with prostate cancer.
Scott T. Tagawa, MD, MS, on Compelling ESMO Data for Metastatic Castration-Sensitive Prostate Cancer
October 18th 2021Scott Tagawa, MD, MS, detailed 2 presentations from ESMO’s presidential symposium that he thinks will have an impact on treating patients with metastatic castration-sensitive prostate cancer.
Sintilimab Meets Primary End Point in ORIENT-31 Trial for EGFR+ Non-Squamous NSCLC
October 18th 2021Sintilimab with or without a bevacizumab biosimilar injection, combined with chemotherapy yielded promising findings in a population of patients with EGFR-mutant nonsquamous non–small cell lung cancer who have previously been treated with an EGFR tyrosine kinase inhibitor.
Alicia Morgans, MD, MPH, Discusses Outcomes From the CARD Trial in mCRPC at 2021 ESMO
October 16th 2021CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk survival and progression outcomes from the CARD trial in patients with metastatic castration-resistant prostate cancer.
FDA Approves Companion Diagnostic For Adjuvant Abemaciclib in High-Risk Early Breast Cancer
October 15th 2021The FDA has given the Ki-67 IHC MIB-1 pharmDx assay a companion diagnostic approval for detecting Ki-67 expression in patients with high-risk early breast cancer who are being considered for treatment with abemaciclib.